 Home > Active Ingredient News > Blood System > Blood: Long-term efficacy of zanubrutinib in relapsed/refractory mantle cell lymphoma

Blood: Long-term efficacy of zanubrutinib in relapsed/refractory mantle cell lymphoma

 Last Update: 2022-04-24
 Source: Internet
 Author: User

Tags

1 2 dichlorobutane

which cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bruton's tyrosine kinase (BTK) inhibitors are an established therapy for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL)
.

Zanubrutinib is an anticancer drug independently developed by BeiGene in China

Lymphoma Precision

This study is a multicenter, single-arm, open-label Phase 2 trial conducted in China to evaluate the efficacy and safety of zanubrutinib in relapsed or refractory mantle cell lymphoma
.

Patients aged 18-75 years with definitively diagnosed relapsed or refractory mantle cell lymphoma with measurable disease were recruited to receive zanubrutinib orally (160 mg, 2/day) until progressive disease (PD), intolerable Toxicity, death, or withdrawal from testing
.

The primary endpoint was overall response rate (ORR)

diagnosis

Progression-Free Survival and Overall Productivity in the Overall Population

After a median follow-up of 35.
3 months, the overall response rate was 83.
7%, of which 77.
9% were in complete response , and the median duration of response was not reached
.

The median progression-free survival (PFS) was 33.

The overall response rate reached 83.

Progression-free survival and overall productivity in patients with different responses

The safety profile did not change significantly with extended follow-up
.

The most common all-grade adverse reactions were decreased neutrophil count (46.

Infect

In conclusion, this study suggests that patients with relapsed/refractory mantle cell lymphoma can achieve durable remission with zanubrutinib with good safety

Patients with relapsed /refractory mantle cell lymphoma can achieve durable responses with zanubrutinib and have a good safety profile mitigation with good security

Original source:

Song Yuqin, Zhou Keshu, Zou De-Hui et al.

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$200-250/G FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.